The chemical hunt for the identification of drugable targets.

Chemical biology has emerged as a new scientific discipline to change the way scientists approach and study the interface between chemistry, biology, and physics. By integrating the knowledge base of the human genome with the power of diverse and flexible chemical technology platforms, the ultimate goal is to define the 'rules of engagement' for small molecules and their use in basic biology and in drug discovery. Herein, we highlight the current counterpoles of the chemical biology philosophy in the framework between conformational diversity and informational complexity. Expanding the growing molecular recognition information matrix into classification of diseases and immediate mechanistic in-vivo proof of concept models represent the next development phase in a field that, unlike any other due to its multidisciplinary nature, unifies basic scientists and drug discoverers.

[1]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[2]  R. Falchetto,et al.  SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. , 2004, Analytical biochemistry.

[3]  Peter G Schultz,et al.  An approach to genomewide screens of expressed small interfering RNAs in mammalian cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Matthew Bogyo,et al.  A Role for the Protease Falcipain 1 in Host Cell Invasion by the Human Malaria Parasite , 2002, Science.

[5]  Andy Vinter,et al.  Peptides to non-peptides: leads from structureless virtual screening , 2004 .

[6]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[7]  C. Lieber,et al.  Nanowire Nanosensors for Highly Sensitive and Selective Detection of Biological and Chemical Species , 2001, Science.

[8]  P. Schultz,et al.  Profiling protein function with small molecule microarrays , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Haggarty,et al.  Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. , 2003, Chemistry & biology.

[10]  S. Schreiber.  Chemical genetics resulting from a passion for synthetic organic chemistry. , 1998, Bioorganic & medicinal chemistry.

[11]  Steven L. Dixon,et al.  Bioactive Diversity and Screening Library Selection via Affinity Fingerprinting , 1998, J. Chem. Inf. Comput. Sci..

[12]  H. Waldmann.  At the crossroads of chemistry and biology. , 2003, Bioorganic & medicinal chemistry.

[13]  Peter G. Schultz,et al.  Synthetic small molecules that control stem cell fate , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Meldal.  The one-bead two-compound assay for solid phase screening of combinatorial libraries. , 2002, Biopolymers.

[15]  A. Eliseev,et al.  Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target. , 2003, Journal of medicinal chemistry.

[16]  J. Claverie,et al.  What If There Are Only 30,000 Human Genes? , 2001, Science.

[17]  P. Taylor,et al.  Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. , 2002, Angewandte Chemie.

[18]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[19]  Dale L Boger,et al.  Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. , 2003, Angewandte Chemie.

[20]  K. Lam,et al.  Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. , 2003, Accounts of chemical research.

[21]  Matthew A. Cooper,et al.  Optical biosensors in drug discovery , 2002, Nature Reviews Drug Discovery.

[22]  J. Drews,et al.  Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.

[23]  Kit S Lam,et al.  Therapeutic cancer targeting peptides. , 2002, Biopolymers.

[24]  Stuart L Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[25]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[26]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.

[27]  Peter G Schultz,et al.  Small molecules that induce cardiomyogenesis in embryonic stem cells. , 2004, Journal of the American Chemical Society.

[28]  T. Groth,et al.  Automated Sorting of Beads from a “One-Bead-Two-Compounds” Combinatorial Library of Metalloproteinase Inhibitors , 2003 .

[29]  C. Wermuth.  Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.

[30]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[31]  Julian L Griffin,et al.  Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. , 2003, Current opinion in chemical biology.

[32]  A. Eliseev,et al.  Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Matthew A. Cooper,et al.  Direct and sensitive detection of a human virus by rupture event scanning , 2001, Nature Biotechnology.

[34]  D. Falb,et al.  Chemical genomics: bridging the gap between the proteome and therapeutics. , 2002, Current opinion in drug discovery & development.

[35]  Wolfgang Jahnke,et al.  Second-site NMR screening and linker design. , 2003, Current topics in medicinal chemistry.

[36]  B. Andrews,et al.  Old Drugs, New Tricks Using Genetically Sensitized Yeast to Reveal Drug Targets , 2004, Cell.

[37]  Chi‐Huey Wong,et al.  A Potent and Highly Selective Inhibitor of Human α-1,3-Fucosyltransferase via Click Chemistry , 2003 .

[38]  Young-Tae Chang,et al.  Tagged library approach to chemical genomics and proteomics. , 2004, Current opinion in chemical biology.

[39]  D. Vetter.  Chemical microarrays, fragment diversity, label‐free imaging by plasmon resonance—a chemical genomics approach , 2002, Journal of cellular biochemistry. Supplement.

[40]  Gang Liu,et al.  Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[41]  T. Mitchison,et al.  Phenotypic screening of small molecule libraries by high throughput cell imaging. , 2003, Combinatorial chemistry & high throughput screening.

[42]  I. Wilson,et al.  Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.

[43]  Horst Kessler,et al.  Nonpeptidic αv β3 Integrin Antagonist Libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. , 2001, Angewandte Chemie.